Santhosh Mathews, MD
Interventional Cardiology · Bradenton, FLNPI 1568588127
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Penumbra, Inc. accounts for 63.1% of it on its own, with 58 other manufacturers making up the rest. Among interventional cardiology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,910 payments — averaging $729.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$879K
- Reflow Medical Inc$165K
- Philips North America LLC$129K
- Boston Scientific$56K
- Shockwave Medical, Inc$39K
- Devoro Medical Inc.$22K
- plus $102K from 53 others
Across 175 payments — averaging $1892.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Penumbra, Inc.$73K
- Boston Scientific$59K
- Contego Medical, Inc$55K
- M.a. Med Alliance S.A.$52K
- Abbott$52K
- Cagent Vascular Inc$11K
- plus $30K from 8 others
Across 3 payments — averaging $8800.00 each. An ownership or investment interest held by the physician or an immediate family member.
- Contego Medical, Inc$26K
What the payments were for
- Consulting fees$293,65021%
- Speaking & faculty fees$739,45653%
- Travel & lodging$279,97320%
- Food & beverage$79,9936%
- Gifts$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$678,337
- Indigo$221,465
- (9520) IGT Devices Undivided$44,041
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$38,125
- US Und$24,444
- WOLF$21,996
- IGT D Peripheral$17,020
- Serrantor$16,706
- (7881) Ultrasound Und$11,000
- (6361) Core Mobile$8,860
- Penumbra Ruby Coil$7,497
- GENERAL THROMBECTOMY$7,209
- GENERAL - THERAPIES$6,865
- RUBY Coil$6,774
- ELUVIA$6,000
- Spectranetics Undiv$5,691
- Diamondback Peripheral$5,067
- Asahi Interventional Radiology Wires$5,000
- Venous Wolf$4,910
- Neuroguard$4,700
How this compares
$1,393,081 in reported general payments places this provider in the 95th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 465 | $493,949 |
| XareltoRivaroxaban | 195 | $208,379 |
| Repatha SureclickEvolocumab | 70 | $84,357 |
| EntrestoSacubitril/Valsartan | 72 | $84,078 |
| JardianceEmpagliflozin | 81 | $61,008 |
| Praluent PenAlirocumab | 45 | $44,347 |
| BrilintaTicagrelor | 25 | $21,552 |
| Repatha SyringeEvolocumab | 12 | $10,468 |
| ClopidogrelClopidogrel Bisulfate | 1,051 | $9,515 |
| Rosuvastatin Calcium | 816 | $8,259 |
| NexletolBempedoic Acid | 18 | $8,001 |
| Metoprolol Succinate | 742 | $6,995 |
| Ezetimibe | 290 | $5,275 |
| Atorvastatin Calcium | 619 | $5,163 |
| Valsartan | 164 | $4,544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $13 | $493,949465 claims |
| Johnson & JohnsonXarelto | $38 | $208,379195 claims |
| NovartisEntresto | $48 | $84,07872 claims |
| AstraZenecaBrilinta | $23 | $21,55225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Bradenton
- Arthur LeeGainesville$1.8M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Zahid AminOrlando$635K
- Rohit AminPensacola$560K
- Eduardo de MarchenaMiami$498K
- Dominick AngiolilloJacksonville$387K
- Miguel DiazHialeah$383K
- Douglas EbersoleLakeland$373K
- Amit SharmaMerritt Island$341K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.